Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin premedication for anxious dental patients
2022-003117-11Phase 2Completed
- Sponsor
- Dentlabe
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of oxytocin in anxiety disorder and Dental anxiety, sponsored by Dentlabe. Primary endpoint: Treatment discontinuation due to adverse events. Started Aug 2023; status: completed.
02
Drugs
oxytocin
03
Conditions
anxiety disorderDental anxiety
Beyond the preview
Go deeper on 2022-003117-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003117-11.